Literature DB >> 23152636

Secondary prevention in patients with vascular disease. A population based study on the underuse of recommended medications.

Yannick Béjot1, Marianne Zeller, Luc Lorgis, Odile Troisgros, Corine Aboa-Eboulé, Guy-Victor Osseby, Maurice Giroud, Yves Cottin.   

Abstract

OBJECTIVES: To investigate the premorbid use of secondary prevention medications in patients with recurrent vascular events.
DESIGN: Prospective, observational, population based study.
SETTING: The Dijon Stroke Registry and the registry of myocardial infarction of Dijon and Côte d'Or, France. PATIENTS: All patients with cerebral ischaemia (ischaemic stroke or transient ischaemic attacks) or coronary artery disease (CAD) and a history of vascular disease (cerebral ischaemia, CAD or peripheral arterial disease (PAD)) in Dijon, France from 2006 to 2010. MAIN OUTCOME MEASURES: Data on medical history and prior use of treatments were collected. Mutivariate analyses were performed to identify predictors of the use of medications.
RESULTS: 867 patients (614 cerebral ischaemia and 253 CAD) were recorded including 448 (51.7%) with a history of cerebral ischaemia only, 191 (22.0%) with a history of CAD only, 68 (7.8%) with a history of PAD only and 160 (18.5%) with a history of polyvascular disease. In these 867 patients, 57.3% were on antithrombotic therapy, 61.2% were treated with antihypertensive drugs, 32.9% received statins and only 23.6% were on an optimal regimen, defined as a combination of the three therapies. Compared with patients with previous CAD only, those with previous cerebral ischaemia only were less likely to be receiving each of these treatments or to receive an optimal regimen (OR=0.17, 95% CI 0.14 to 0.26, p<0.001).
CONCLUSIONS: Our findings underline the fact that the underuse of secondary preventive therapies is common in patients with recurrent vascular events, especially those with previous cerebral ischaemia. This underuse could be targeted to reduce recurrent vascular events.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152636     DOI: 10.1136/jnnp-2012-303267

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  6 in total

1.  Recurrent stroke in midlife is associated with not having a primary care physician.

Authors:  Rebecca J Lank; Lynda D Lisabeth; Brisa N Sánchez; Darin B Zahuranec; Kevin A Kerber; Lesli E Skolarus; James F Burke; Deborah A Levine; Erin Case; Devin L Brown; Lewis B Morgenstern
Journal:  Neurology       Date:  2019-01-04       Impact factor: 9.910

2.  Optimal combination secondary prevention drug treatment and stroke outcomes.

Authors:  Jong-Ho Park; Bruce Ovbiagele
Journal:  Neurology       Date:  2014-11-19       Impact factor: 9.910

3.  Stroke: LDL and stroke risk—clinical practice or target practice?

Authors:  Jong-Ho Park; Bruce Ovbiagele
Journal:  Nat Rev Neurol       Date:  2014-12-09       Impact factor: 42.937

4.  Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study.

Authors:  Nele Laleman; Séverine Henrard; Marjan van den Akker; Geert Goderis; Frank Buntinx; Gijs Van Pottelbergh; Bert Vaes
Journal:  BMC Cardiovasc Disord       Date:  2018-11-06       Impact factor: 2.298

5.  Clinical and imaging services for TIA and minor stroke: results of two surveys of practice across the UK.

Authors:  Miriam Brazzelli; Kirsten Shuler; Zahid Quayyum; Donald Hadley; Keith Muir; Paul McNamee; Janet De Wilde; Martin Dennis; Peter Sandercock; Joanna M Wardlaw
Journal:  BMJ Open       Date:  2013-08-07       Impact factor: 2.692

6.  Impact of age on cardiovascular drug use in patients with chronic kidney disease.

Authors:  Cédric Villain; Sophie Liabeuf; Marie Metzger; Christian Combe; Denis Fouque; Luc Frimat; Christian Jacquelinet; Maurice Laville; Serge Briançon; Ronald L Pisoni; Nicolas Mansencal; Bénédicte Stengel; Ziad A Massy
Journal:  Clin Kidney J       Date:  2019-06-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.